AGÕæÈ˹ٷ½

STOCK TITAN

Rockwell Med Inc SEC Filings

RMTI NASDAQ

Welcome to our dedicated page for Rockwell Med SEC filings (Ticker: RMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Rockwell Medical’s filings rarely stop at numbers—each 8-K can hint at FDA feedback, every 10-K buries pages of dialysis supply logistics, and Form 4 insider selling often precedes capital raises. Finding those signals is tough when disclosures stretch past 200 pages. That’s the problem investors face with Rockwell Medical’s complex renal-care narrative.

Stock Titan solves it. Our AI reads every Rockwell Medical annual report 10-K simplified, each Rockwell Medical quarterly earnings report 10-Q filing, and even the swift Rockwell Medical 8-K material events explained, then delivers clear summaries you can scan in minutes. Need to track Rockwell Medical insider trading Form 4 transactions? Receive Rockwell Medical Form 4 insider transactions real-time and view executive stock transactions Form 4 alongside plain-English context. Trying to compare margins quarter over quarter? Our AI maps segment data automatically, turning “other COGS� footnotes into usable charts.

Because dialysis economics hinge on concentrate pricing and Triferic adoption, you’ll discover exactly where management discloses reimbursement updates, patent expirations, and manufacturing capacity—all flagged inside the filing. Use cases include:

  • Review Rockwell Medical proxy statement executive compensation before voting
  • Monitor cash-burn trends with Rockwell Medical earnings report filing analysis
  • Spot board purchases via Rockwell Medical insider trading Form 4 transactions alerts
Understanding Rockwell Medical SEC documents with AI means you no longer sift through boilerplate—real-time updates, comprehensive coverage of every form, and expert commentary appear the moment EDGAR publishes. Complex biotech disclosures, explained simply.

Rhea-AI Summary

Rockwell Medical (RMTI) reported a sharp decline in sales following reduced volumes from its largest customer. Net sales were $16.1 million for the quarter (down 38% year-over-year) and $35.0 million for the six months (down 28%). Gross margin held near 16%, but the company recorded a net loss of $1.5 million for the quarter and $3.0 million year-to-date, driven largely by a $9.9 million quarterly reduction in DaVita purchases and a $14.6 million reduction for the six-month period.

Liquidity sources include $18.4 million of cash, cash equivalents and short-term investments, $21.1 million available under an ATM facility, and net working capital of $20.7 million; management believes these resources are sufficient for at least the next twelve months. The Company has an outstanding term loan with a net carrying amount of $8.6 million, current deferred consideration of $2.5 million, and completed remediation with its lender by submitting updated projections. The Company also disclosed a new multimillion-dollar supply agreement with IRC with three-year utilization commitments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
quarterly report
-
Rhea-AI Summary

Rockwell Medical, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025, and attached that press release as Exhibit 99.1 to this Current Report on Form 8-K. The company explicitly states the information in Item 2.02 and Exhibit 99.1 is being furnished and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into Securities Act filings except by specific reference. Item 9.01 lists the furnished exhibits: Exhibit 99.1 (press release) and Exhibit 104 (Cover Page Interactive Data File in Inline XBRL). The report is signed on behalf of the registrant by Mark Strobeck, Chief Executive Officer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Rockwell Medical, Inc. (RMTI) filed a Form 144 indicating that 6,926 common shares may be sold under Rule 144. The proposed transaction will be executed through Raymond James & Associates on or after 1 July 2025.

The shares were acquired via RSU vesting on 17 March 2024. At the indicated aggregate market value of $5,536, the filing equates to roughly 0.02 % of the company’s 34.17 million shares outstanding; therefore, the sale is immaterial to share-count dilution and likely has negligible impact on liquidity.

The seller identified in the past-sales table is Mark Strobeck, who disposed of an identical 6,926-share block on 1 April 2025 for gross proceeds of $7,263. The current notice affirms that the filer is not aware of undisclosed material adverse information and is acting in compliance with SEC Rule 144 and related insider-trading provisions.

Overall, the filing represents routine insider portfolio management rather than a signal of fundamental change.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

What is the current stock price of Rockwell Med (RMTI)?

The current stock price of Rockwell Med (RMTI) is $1.045 as of August 13, 2025.

What is the market cap of Rockwell Med (RMTI)?

The market cap of Rockwell Med (RMTI) is approximately 32.3M.
Rockwell Med Inc

NASDAQ:RMTI

RMTI Rankings

RMTI Stock Data

32.34M
29.11M
13.81%
20.76%
0.44%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States
WIXOM